Cytosolic 5′-Nucleotidase 1A As a Target of Circulating Autoantibodies in Autoimmune Diseases

Arthritis Care and Research

Volumn 68, Issue 1, 2016, Pages 66-71

  Lloyd, Thomas E ^a   Christopher Stine, Lisa ^a   Pinal Fernandez, Iago ^b   Tiniakou, Eleni ^a   Petri, Michelle ^a   Baer, Alan ^a   Danoff, Sonye K ^a   Pak, Katherine ^c   Casciola Rosen, Livia A ^a   Mammen, Andrew L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CYTOSOLIC 5' NUCLEOTIDASE 1A; NT5C1A ANTIBODY; NUCLEOTIDASE; UNCLASSIFIED DRUG; 5' NUCLEOTIDASE; BIOLOGICAL MARKER; NT5C1A PROTEIN, HUMAN;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTHROPATHY; ARTICLE; AUTOIMMUNE DISEASE; CALCINOSIS; CONTROLLED STUDY; DERMATOMYOSITIS; FEMALE; FEVER; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; INCLUSION BODY MYOSITIS; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MUSCLE BIOPSY; MUSCLE WEAKNESS; PAPULE; PATHOGENESIS; POLYMYOSITIS; PREVALENCE; PROTEIN TARGETING; RASH; RAYNAUD PHENOMENON; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; AGED; AUTOIMMUNE DISEASES; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; ENZYMOLOGY; IMMUNOLOGY; MIDDLE AGED; PREDICTIVE VALUE; SEROLOGY;

5'-NUCLEOTIDASE; AGED; AUTOANTIBODIES; AUTOIMMUNE DISEASES; BIOMARKERS; CASE-CONTROL STUDIES; DERMATOMYOSITIS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SEROLOGIC TESTS;

EID: 84956631248     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22600     Document Type: Article

References (16)

1. Yoshida S, Akizuki M, Mimori T, Yamagata H, Inada S, Homma M., The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue diseases: A marker for a subset of polymyositis with interstitial pulmonary fibrosis. Arthritis Rheum 1983; 26: 604-11.
2. Marguerie C, Bunn CC, Beynon HL, Bernstein RM, Hughes JM, So AK, et al., Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med 1990; 77: 1019-38.
3. Oke V, Wahren-Herlenius M., The immunobiology of Ro52 (TRIM21) in autoimmunity: A critical review. J Autoimmun 2012; 39: 77-82.
4. Rider LG, Miller FW., Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies. JAMA 2011; 305: 183-90.
5. Larman HB, Salajegheh M, Nazareno R, Lam T, Sauld J, Steen H, et al., Cytosolic 5′-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol 2013; 73: 408-18.
6. Pluk H, van Hoeve BJ, van Dooren SH, Stammen-Vogelzangs J, van der Heijden A, Schelhaas HJ, et al., Autoantibodies to cytosolic 5′-nucleotidase 1A in inclusion body myositis. Ann Neurol 2013; 73: 397-407.
7. Lloyd TE, Mammen AL, Amato AA, Weiss MD, Needham M, Greenberg SA., Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology 2014; 83: 426-33.
8. Brady S, Squier W, Hilton-Jones D., Clinical assessment determines the diagnosis of inclusion body myositis independently of pathological features. J Neurol Neurosurg Psychiatry 2013; 84: 1240-6.
9. Bohan A, Peter JB., Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344-7.
10. Bohan A, Peter JB., Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292: 403-7.
11. Hall JC, Casciola-Rosen L, Samedy LA, Werner J, Owoyemi K, Danoff SK, et al., Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: Expanding the clinical spectrum. Arthritis Care Res (Hoboken) 2013; 65: 1307-15.
12. Hunsucker SA, Mitchell BS, Spychala J., The 5′-nucleotidases as regulators of nucleotide and drug metabolism. Pharmacol Ther 2005; 107: 1-30.
13. Careddu MG, Allegrini S, Pesi R, Camici M, Garcia-Gil M, Tozzi MG., Knockdown of cytosolic 5′-nucleotidase II (cN-II) reveals that its activity is essential for survival in astrocytoma cells. Biochim Biophys Acta 2008; 1783: 1529-35.
14. Kulkarni SS, Karlsson HK, Szekeres F, Chibalin AV, Krook A, Zierath JR., Suppression of 5′-nucleotidase enzymes promotes AMP-activated protein kinase (AMPK) phosphorylation and metabolism in human and mouse skeletal muscle. J Biol Chem 2011; 286: 34567-74.
15. Greenberg SA., Pathogenesis and therapy of inclusion body myositis. Curr Opin Neurol 2012; 25: 630-9.
16. Montano-Loza AJ, Shums Z, Norman GL, Czaja AJ., Prognostic implications of antibodies to ro/SSA and soluble liver antigen in type 1 autoimmune hepatitis. Liver Int 2012; 32: 85-92.